Catalyst Pharmaceuticals Inc CPRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/03/24 EDT

14.93

+0.21 (+1.43%)

Volume

30,803

14.72

-0.30 (-2.00%)

Volume

1,129,115

52 week range

11.09 - 17.76

Open15.29
Day High15.35
Day Low14.70
Prev Close15.02
52 Week High17.76
52 Week High Date05/08/23
52 Week Low11.09
52 Week Low Date06/01/23

Key Stats

Market Cap1.737B
Shares Out118.01M
10 Day Average Volume1.62M
Dividend-
Dividend Yield-
Beta0.73
YTD % Change-12.43

KEY STATS

Open15.29
Day High15.35
Day Low14.70
Prev Close15.02
52 Week High17.76
52 Week High Date05/08/23
52 Week Low11.09
52 Week Low Date06/01/23
Market Cap1.737B
Shares Out118.01M
10 Day Average Volume1.62M
Dividend-
Dividend Yield-
Beta0.73
YTD % Change-12.43

RATIOS/PROFITABILITY

EPS (TTM)0.61
P/E (TTM)24.16
Fwd P/E (NTM)14.78
EBITDA (TTM)119.693M
ROE (TTM)20.75%
Revenue (TTM)398.204M
Gross Margin (TTM)86.95%
Net Margin (TTM)17.93%
Debt To Equity (MRQ)-

EVENTS

Earnings Date05/30/2024
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Catalyst Pharmaceuticals Inc

Jim Cramer lays out his top small-cap healthcare picksApril 5, 2024CNBC.com
Jim Cramer recommends five small-cap health-care stocksApril 5, 2024CNBC.com

Content From Our Affiliates

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024April 22, 2024TipRanks

Profile

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII...

Patrick McEnany

Non-Executive Chairman of the Board

Richard Daly

Chief Executive Officer, Director

Steven Miller Ph.D.

Executive Vice President, Chief Operating and Scientific Officer

Michael Kalb

Chief Financial Officer, Executive Vice President

Jeffrey Del Carmen

Executive Vice President, Chief Commercial Officer

Alicia Grande CPA

Vice President, Treasurer

Address

355 ALHAMBRA CIRCLE, SUITE 801

Coral Gables, FL

33134

United States

https://catalystpharma.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
BEAM Beam Therapeutics Inc	23.13	+0.41	+1.80%
VCYT Veracyte Inc	20.35	+0.16	+0.79%
TWST Twist Bioscience Corp	41.21	+9.20	+28.74%
DNA Ginkgo Bioworks	0.955	+0.0939	+10.9047%
DNLI Denali Therapeutics Inc	17.14	+0.33	+1.96%